Weekly Analysts’ Ratings Updates for Repligen (RGEN)

Repligen (NASDAQ: RGEN) recently received a number of ratings updates from brokerages and research firms:

• 4/20/2026 – Repligen had its price target lowered by Canaccord Genuity Group Inc. from $165.00 to $145.00. They now have a “hold” rating on the stock.
• 4/17/2026 – Repligen was given a new $160.00 price target by Rothschild & Co Redburn. They now have a “buy” rating on the stock.
• 4/17/2026 – Repligen was upgraded by Rothschild & Co Redburn to “strong-buy”.
• 4/17/2026 – Repligen is now covered by Roth Mkm. They set a “buy” rating and a $160.00 price target on the stock.
• 4/14/2026 – Repligen had its price target lowered by Barclays PLC from $175.00 to $145.00. They now have an “overweight” rating on the stock.
• 3/23/2026 – Repligen had its price target raised by HC Wainwright from $180.00 to $208.00. They now have a “buy” rating on the stock.
• 3/3/2026 – Repligen was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.